Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ivermectin.

George W Elgart1, Terri L Meinking

  • 1Department of Dermatology and Cutaneous Surgery, University of Miami School of Medicine, 1444 North West 9th Avenue, Miami, FL 33136, USA. gelgart@med.miami.edu

Dermatologic Clinics
|May 22, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy of combined topical imiquimod, 5-fluorouracil, and tretinoin in the treatment of a basaloid atypical proliferation on the plantar surface in a patient who is nonsyndromic for basal cell nevus syndrome.

JAAD case reports·2026
Same author

Conjunctival keratoacanthoma: a clinical and histopathological case series.

Canadian journal of ophthalmology. Journal canadien d'ophtalmologie·2024
Same author

Extensive asymptomatic violaceous plaques on the upper body of a middle-aged man.

Clinical and experimental dermatology·2024
Same author

Immune checkpoint inhibitor associated epidermal necrosis, beyond SJS and TEN: a review of 98 cases.

Archives of dermatological research·2024
Same author

Cutaneous Mycobacterium avium-intracellulare infection masquerading as sarcoidosis.

Pediatric dermatology·2024
Same author

Upregulation of Insulin-like Growth Factor-1 Receptor Expression in Pretibial Myxedema: Evidence for a Treatment Target.

The American Journal of dermatopathology·2023

Ivermectin, a macrocyclic lactone, is an effective antiparasitic drug for treating river blindness and ectoparasitic infestations. Its minor side effects and good patient acceptance make it a valuable therapeutic option.

Area of Science:

  • Pharmacology
  • Tropical Medicine
  • Public Health

Background:

  • Ivermectin is a macrocyclic lactone antiparasitic.
  • It is approved for human use and effective against river blindness.
  • Growing resistance to topical therapies necessitates alternative treatments.

Purpose of the Study:

  • To review the efficacy and safety of ivermectin.
  • To highlight its role in public health and off-label applications.
  • To assess ivermectin's position in the therapeutic armamentarium.

Main Methods:

  • Literature review of ivermectin's clinical applications.
  • Analysis of efficacy data for river blindness and ectoparasitic infestations.
  • Evaluation of safety profiles and patient acceptance.

Related Experiment Videos

Main Results:

  • Ivermectin has successfully reduced river blindness as a public health issue.
  • Off-label use shows promising results for ectoparasitic infestations.
  • Side effects are generally minor, with good patient acceptance.

Conclusions:

  • Ivermectin is a significant advancement in antiparasitic therapy.
  • It should be considered for appropriate clinical cases, especially with rising resistance to other treatments.
  • Its established efficacy and safety profile support its continued use.